Related Experiment Videos
Calcineurin inhibitors and post-transplant hyperlipidaemias
R Moore1, D Hernandez, H Valantine
1University of Cardiff, Wales, United Kingdom. Richard.Moore@UHW-TR.wales.nhs.uk
Insights
Post-transplant hyperlipidaemia (PTHL) is a common complication in transplant recipients, linked to immunosuppressants. Management involves diet, reduced corticosteroids, and lipid-lowering drugs to mitigate cardiovascular risks.
Area of Science:
- Nephrology
- Cardiology
- Immunology
Background:
- Cardiovascular disease is the primary cause of death in transplant recipients.
- Post-transplant hyperlipidaemia (PTHL) is a significant complication, characterized by elevated cholesterol and triglycerides.
- Immunosuppressants like corticosteroids, rapamycins, and calcineurin inhibitors contribute to PTHL.
Purpose of the Study:
- To review the role of immunosuppressants in post-transplant hyperlipidaemia (PTHL).
- To discuss the management strategies for PTHL in transplant recipients.
- To highlight the need for further research on immunosuppressants' long-term effects.
Main Methods:
- Literature review of studies on immunosuppressants and post-transplant hyperlipidaemia (PTHL).
- Analysis of the impact of calcineurin inhibitors (tacrolimus, cyclosporin) and corticosteroids on lipid profiles.
- Evaluation of current management approaches for PTHL.
Main Results:
- PTHL is frequently observed with calcineurin inhibitor-based immunosuppression.
- Differences in PTHL incidence/severity may be linked to corticosteroid dosage variations.
- Evidence on specific immunosuppressant-related differences in PTHL is limited.
Conclusions:
- PTHL is a manageable complication in transplant recipients.
- Effective management includes dietary changes, corticosteroid adjustment, and lipid-lowering medications.
- Further research is crucial to understand long-term cardiovascular impact and graft function related to immunosuppressants.
Abstract:
Cardiovascular disease is now the leading cause of death in transplant recipients. This is due, in part, to the vulnerability of these patients to a complicated set of conditions including hypertension, diabetes mellitus, and post-transplant hyperlipidaemia (PTHL). PTHL is characterised by persistent elevations in total serum cholesterol, low density lipoprotein cholesterol and triglyceride levels. The causes of PTHL are complex and not fully understood, however several classes of immunosuppressants including the corticosteroids, rapamycins and calcineurin inhibitors, appear to play a role. PTHL has been observed in most studies in which patients received calcineurin inhibitor-based regimens, and has been observed with both tacrolimus and cyclosporin. Comparing these calcineurin inhibitors with regard to the relative incidence or severity of PTHL occurring during treatment is difficult because of the use of higher doses of corticosteroids in cyclosporin-based regimens, as compared with tacrolimus-based regimens. However, current expert opinion suggests that the discrepancies in the relative incidence and severity of PTHL are largely accounted for by this difference in corticosteroid dose. At this point in time, evidence for potential differences is scant and inconclusive. Further study is needed, not only to investigate differences in lipid profile, but also of the relative effects of these immunosuppressants on long term graft function as well as on cardiovascular morbidity and mortality. PTHL can be successfully managed with a combination of dietary management, reduction and, if appropriate, withdrawal of corticosteroids, and the administration of lipid-lowering drugs. With this combination of therapeutic options, the threats to long term health posed by PTHL may be effectively addressed.